EDAP TMS SA : University of Chicago Medicine Becomes First Hospital in the Midwest to Acquire Breakthrough Focal One® HIFU Advanced Robotic Technology for Prostate Cancer Treatment
EDAP TMS SA : University of Chicago Medicine Becomes First Hospital in the Midwest to Acquire Breakthrough Focal One® HIFU Advanced Robotic Technology for Prostate Cancer Treatment
Focal One's precision means qualifying prostate cancer patients can forego prostate removal surgery and avoid life-altering side effects including incontinence and impotence
Focal One HIFU (high intensity focused ultrasound) makes it possible for doctors to deliver a non-invasive precision treatment to the prostate-without removing it-reducing the likelihood of negative side effects like incontinence and impotence commonly related to surgical treatments.
UChicago Medicine is the fifth medical center in the U.S. to acquire Focal One since the new system for prostate tissue ablation received 510(k) clearance from the
"Focal One specifically targets the diseased tissue and allows the patient to retain his prostate and his quality of life," said Arieh Shalhav, MD, Fritz and Mary Lee Duda Family Chair, Chief, Section of Urologic Surgery, Professor of Surgery and the
"We are honored to add the
About UChicago Medicine
About
A recognized leader in the global therapeutic ultrasound market for almost 40 years,
Forward-Looking Statements
In addition to historical information, this press release may contain forward-looking statements. Such statements are based on management's current expectations and are subject to a number of risks and uncertainties, including matters not yet known to us or not currently considered material by us, and there can be no assurance that anticipated events will occur or that the objectives set out will actually be achieved. Important factors that could cause actual results to differ materially from the results anticipated in the forward-looking statements include, among others, the clinical status and market acceptance of our HIFU devices and the continued market potential for our lithotripsy device. Factors that may cause such a difference also may include, but are not limited to, those described in the Company's filings with the
###
Contact PR Media
sgordon@g2comm.com
(480) 685-3252
Investor Contact
LifeSci Advisors, LLC
212-915-2568
jeremy@lifesciadvisors.com
Company Contact
Investor Relations / Legal Affairs
+33 4 72 15 31 50
bconfort@edap-tms.com
Source: EDAP TMS S.A.